Market brief
European Anti-Infectives & AMR 2026: Antibacterials, Antifungals, Sepsis, and Pathogen Diagnostics
European anti-infectives and antimicrobial-resistance therapeutics in 2026 span 16 directory-surfaced operators across three overlapping tracks: clinical-stage and commercial anti-infective therapeutics (Basilea, BioVersys, Biosergen, Modus Therapeutics, Hamlet BioPharma, AlgiPharma), pathogen + AMR molecular diagnostics (ArcDia, Abacus Diagnostica, Altona Diagnostics, Spindiag, Genomtec, Scope Fluidics, Bioavlee), and infectious disease vaccine + surveillance + preparedness infrastructure (ExpreS2ion, Abera Bioscience, Statens Serum Institut). Switzerland concentrates the directory’s anti-infective therapeutic operators (Basilea, BioVersys). Sweden adds antifungal (Biosergen) and sepsis (Modus). Germany hosts large-cap infectious-disease molecular diagnostics (Altona, Spindiag). Finland and Poland add the rapid molecular pathogen-detection layer (ArcDia, Abacus, Genomtec, Scope Fluidics, Bioavlee). Denmark hosts the European public-health infectious-disease reference + surveillance operator (Statens Serum Institut). The European Vaccines Landscape 2026 brief covers infectious-disease vaccine development; the European Diagnostics Landscape 2026 brief covers the wider IVD layer.
Summary
Key findings
Basilea Pharmaceutica (Basel, Switzerland) is the directory-surfaced commercial anti-infectives operator with Cresemba (isavuconazole, broad-spectrum antifungal for invasive aspergillosis and mucormycosis) and Zevtera (ceftobiprole, broad-spectrum cephalosporin for bacteraemia + community-acquired and hospital-acquired pneumonia, FDA approval April 2024) — alongside oncology pipeline.
BioVersys (Basel, Switzerland) is the directory-surfaced antibacterial-discovery + AMR-biology clinical-stage operator, developing alpibectir (BVL-GSK098) for tuberculosis as a VirS-targeting transcriptional modulator boosting MymA bioactivation of ethionamide (partnered with GSK) and BV100 for carbapenem-resistant Acinetobacter baumannii bloodstream infection.
Biosergen (Solna, Sweden) develops BSG005 (nystatin-derived polyene macrolide engineered to reduce nephrotoxicity while retaining fungicidal activity) for invasive fungal infections; Modus Therapeutics (Stockholm) develops sevuparin for sepsis + severe inflammation + malaria; Hamlet BioPharma (Lund) develops Alpha1H peptide therapeutic for bladder cancer + infection therapeutics; AlgiPharma (Sandvika, Norway) develops OligoG alginate oligomer for biofilm disruption + cystic fibrosis + AMR.
European pathogen + AMR molecular diagnostics concentrate at seven directory operators: ArcDia (Turku, automated IVD infectious disease), Abacus Diagnostica (Turku, rapid PCR + sample-to-answer), Altona Diagnostics (Hamburg, real-time PCR global infectious disease), Spindiag (Freiburg, point-of-care multiplex PCR respiratory pathogens), Genomtec (Wroclaw, point-of-care isothermal molecular diagnostics + SNAAT cartridges), Scope Fluidics (Warsaw, AMR susceptibility microfluidics via BacterOMIC + rapid PCR via PCR|ONE), Bioavlee (Wroclaw, AI microscopy + rapid bacterial identification).
Numbers
Quick numbers
Analysis
Basilea and BioVersys: the Swiss anti-infectives cluster
Switzerland concentrates the directory-surfaced anti-infectives therapeutic operators through Basilea (Basel) and BioVersys (Basel). Basilea Pharmaceutica is the commercial anti-infectives + oncology operator with Cresemba (isavuconazole, broad-spectrum antifungal for invasive aspergillosis and mucormycosis, commercialised by Astellas in the US, with Pfizer holding Europe + China + Asia-Pacific rights and multiple ex-US territory partners) and Zevtera (ceftobiprole, broad-spectrum cephalosporin for bacteraemia + community-acquired and hospital-acquired pneumonia, FDA approved April 2024 with US commercialisation through Innoviva Specialty Therapeutics). Basilea also develops Fosfomycin IV (zerbaxa-adjacent context), and pipeline anti-infectives + ADC oncology assets. BioVersys (Basel) develops alpibectir (BVL-GSK098, Mycobacterium tuberculosis VirS-targeting transcriptional modulator that boosts MymA-mediated bioactivation of ethionamide, partnered with GSK) and BV100 (rifabutin-based intravenous formulation in Phase 3 RIV-TARGET for hospital- and ventilator-acquired bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii), with anti-resistance + antibacterial pipeline programmes targeting WHO priority pathogens.
Analysis
Antifungal, sepsis, and infection-adjacent therapeutics
Beyond the Swiss anti-infective cluster, the directory surfaces clinical-stage operators across antifungal, sepsis, and infection-adjacent indications. Biosergen (Solna, Sweden) develops BSG005 (encochleated amphotericin B in oral formulation) for invasive fungal infections — addressing the unmet need for orally available systemic antifungals. Modus Therapeutics (Stockholm) develops sevuparin (low-anticoagulant heparin-derived polysaccharide) for sepsis-associated organ failure, severe inflammation, malaria, and anemia of chronic inflammation. Hamlet BioPharma (Lund, Sweden) develops Alpha1H (a synthetic alpha-lactalbumin-derived peptide that forms an active complex with oleic acid, sometimes referred to as alpha1-oleate) for bladder cancer and infection-related therapeutic indications. AlgiPharma (Sandvika, Norway) develops OligoG (low-molecular-weight alginate oligosaccharide) for cystic fibrosis biofilm disruption + antimicrobial resistance — adjacent to the AMR therapeutic layer. Aplagon (Helsinki, Finland) develops APAC for cardiovascular thromboinflammation including infection-associated vascular events (counted as adjacent rather than within the core 16-operator anti-infective tally).
Analysis
Pathogen molecular diagnostics: rapid PCR + isothermal + point-of-care
European pathogen + AMR molecular diagnostics concentrate at seven directory operators. Altona Diagnostics (Hamburg, Germany) is the directory-surfaced global infectious-disease real-time PCR operator with assays across viral, bacterial, and parasitic pathogens used by reference and clinical labs worldwide. Spindiag (Freiburg, Germany) develops the Rhonda point-of-care multiplex PCR system using centrifugal microfluidics for respiratory pathogen detection. ArcDia (Turku, Finland) develops the mariPOC automated IVD platform for infectious disease near-patient testing. Abacus Diagnostica (Turku, Finland) develops the GenomEra sample-to-answer rapid PCR platform for infectious disease + AMR testing. Genomtec (Wroclaw, Poland) develops point-of-care isothermal molecular diagnostics using SNAAT-based cartridge devices. Scope Fluidics (Warsaw, Poland) develops the BacterOMIC AMR + PA-100 point-of-care molecular diagnostics platforms. Bioavlee (Wroclaw, Poland) develops AI microscopy + rapid bacterial identification + point-of-care microbiology workflows.
Analysis
Vaccines, antigen production, and public-health surveillance
The infectious-disease vaccine + antigen + public-health layer adjacent to therapeutic and diagnostic anti-infectives includes three directory operators. ExpreS2ion Biotech (Hørsholm, Denmark) develops the ExpreS2 protein expression platform for vaccine antigen production with applications across malaria, COVID-19, and other infectious-disease vaccines. Abera Bioscience (Uppsala, Sweden) develops nasal vaccines using OMV (outer membrane vesicle) platforms for infectious disease prevention. Statens Serum Institut (Copenhagen, Denmark) is the directory-surfaced European public-health reference operator running infectious-disease surveillance, public-health diagnostics, preparedness, and reference laboratory services. The European Vaccines Landscape 2026 brief covers vaccine development in detail including BioNTech, CureVac, Bavarian Nordic, MinervaX, and Valneva-adjacent operators.
Analysis
Adjacent operators: antimicrobial coatings, biofilm, and aquaculture pathogens
Several directory operators sit adjacent to the core anti-infectives + AMR layer. AlgiPharma’s biofilm-disruption work overlaps with antimicrobial coatings + chronic-wound infection. Angenovo (Rissa, Norway) provides life-science tools distribution + antibody catalog + aquaculture pathogen diagnostics — relevant to the European aquaculture biosecurity layer. The European Diagnostics Landscape 2026 brief covers the wider IVD ecosystem including molecular diagnostics, autoimmunity, oncology, and women’s health diagnostics.
Analysis
How to pick a European anti-infectives + AMR partner in 2026
Match the decision to the indication. Commercial broad-spectrum antifungal partnership: Basilea (Basel, Cresemba). Commercial broad-spectrum cephalosporin: Basilea (Zevtera, FDA-approved April 2024). Antibacterial discovery + AMR-biology + WHO priority pathogen partnership: BioVersys (Basel). Tuberculosis: BioVersys (alpibectir, partnered with GSK). Carbapenem-resistant Acinetobacter: BioVersys (BV100). Oral systemic antifungal: Biosergen (Solna). Sepsis + severe inflammation: Modus Therapeutics (Stockholm). Bladder cancer + infection-related peptide therapeutic: Hamlet BioPharma (Lund). Cystic fibrosis biofilm + AMR: AlgiPharma (Sandvika). Global infectious-disease PCR diagnostics: Altona Diagnostics (Hamburg). Point-of-care multiplex PCR respiratory: Spindiag (Freiburg). Rapid sample-to-answer infectious disease: ArcDia (Turku) or Abacus Diagnostica (Turku). Point-of-care isothermal molecular: Genomtec (Wroclaw). AMR susceptibility microfluidics + rapid PCR: Scope Fluidics (Warsaw, BacterOMIC + PCR|ONE). AI microscopy + rapid bacterial ID: Bioavlee (Wroclaw). Vaccine antigen production: ExpreS2ion (Hørsholm). Nasal OMV vaccines: Abera Bioscience (Uppsala). Public-health reference + surveillance: Statens Serum Institut (Copenhagen). The How to Pick a European Biotech Partner 2026 brief covers cross-modality partner selection.
What to watch
What to watch next
Basilea Zevtera US commercial rollout (Innoviva partnership)
BioVersys alpibectir Phase 3 TB readouts (with GSK) + BV100 Acinetobacter milestones
Biosergen BSG005 polyene antifungal clinical readouts
Modus Therapeutics sevuparin sepsis programme progression
Spindiag + ArcDia + Abacus point-of-care PCR commercial expansion + AMR signal additions
Scope Fluidics BacterOMIC AMR commercial milestones
Statens Serum Institut European infectious-disease preparedness + surveillance disclosures
FAQ
Frequently asked questions
Who is the main European anti-infective therapeutic operator in 2026?
Basilea Pharmaceutica (Basel, Switzerland) is the directory-surfaced commercial anti-infective operator with Cresemba (isavuconazole, broad-spectrum antifungal for invasive aspergillosis + mucormycosis) and Zevtera (ceftobiprole, broad-spectrum cephalosporin for bacteraemia + CAP/HAP, FDA approved April 2024). BioVersys (Basel) is the directory-surfaced antibacterial-discovery + AMR-biology clinical-stage operator with alpibectir (TB, partnered with GSK) and BV100 (carbapenem-resistant Acinetobacter).
What antifungal, sepsis, and infection-adjacent operators does the directory cover?
Biosergen (Solna, Sweden) develops BSG005 (nystatin-derived polyene macrolide engineered to reduce nephrotoxicity while retaining fungicidal activity) for invasive fungal infections. Modus Therapeutics (Stockholm) develops sevuparin for sepsis + severe inflammation + malaria. Hamlet BioPharma (Lund) develops Alpha1H peptide therapeutic for bladder cancer + infection. AlgiPharma (Sandvika) develops OligoG alginate oligomer for cystic fibrosis biofilm + AMR.
Where is European pathogen + AMR molecular diagnostics capacity?
Seven directory operators across rapid PCR, isothermal, and point-of-care. Altona Diagnostics (Hamburg) for global infectious-disease real-time PCR. Spindiag (Freiburg) for point-of-care multiplex PCR respiratory. ArcDia (Turku) for automated near-patient IVD. Abacus Diagnostica (Turku) for rapid sample-to-answer PCR. Genomtec (Wroclaw) for point-of-care isothermal SNAAT cartridges. Scope Fluidics (Warsaw) for AMR microfluidics + BacterOMIC + PCR|ONE. Bioavlee (Wroclaw) for AI microscopy + rapid bacterial identification.
Who runs European infectious-disease vaccine + antigen production?
Three directory operators. ExpreS2ion Biotech (Hørsholm, Denmark) develops the ExpreS2 protein expression platform for vaccine antigen production. Abera Bioscience (Uppsala, Sweden) develops nasal vaccines using OMV platforms. Statens Serum Institut (Copenhagen, Denmark) is the directory-surfaced European public-health reference operator running infectious-disease surveillance + preparedness + reference laboratory services. The European Vaccines Landscape 2026 brief covers infectious-disease vaccine development in wider context.
How does AMR detection differ from general infectious-disease diagnostics?
AMR detection adds susceptibility / resistance-gene detection to pathogen identification. Scope Fluidics (Warsaw) BacterOMIC platform is the directory-surfaced AMR-specific susceptibility microfluidics operator (alongside its PCR|ONE rapid-PCR system). Altona, Spindiag, ArcDia, Abacus, Genomtec, and Bioavlee provide pathogen identification with varying degrees of AMR-relevant signal. Public-health AMR surveillance is handled by Statens Serum Institut (Copenhagen) and national reference laboratories outside the directory scope.
Methodology note
Sources and interpretation
Sources: verified Memel Biotech directory entries for every anti-infective + diagnostic + surveillance operator, official company disclosures, EMA + FDA approval records (Cresemba, Zevtera), public partnership announcements (BioVersys + GSK, Basilea + Astellas + Pfizer + Innoviva), and editorial cross-reference against the European Vaccines Landscape 2026, European Diagnostics Landscape 2026, European Drug Discovery Services 2026, and Polish + Nordic + Swiss + German landscape briefs. The directory entry for each operator links to the authoritative company sources.
Disclaimer
Use limits
This brief is an editorial map of visible European anti-infectives + AMR activity in 2026. Product names, regulatory approvals, partnership scope, and clinical milestones reflect publicly disclosed information as of directory review — verify directly with each operator before engagement, particularly given fast-moving AMR regulatory and commercial developments.
Primary sources
Source list
Related pages
Related directory records
Briefs
Continue through related topics.
A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.